Retatrutide (GLP-1/GIP/Glucagon): 5mg

Description

Retatrutide (ly3437943) -- widely called "reta", "ret", or "glp-3" in the research and biohacking communities -- is a synthetic 39-amino acid triple receptor agonist developed by eli lilly that simultaneously activates glp-1 (glucagon-like peptide-1), gip (glucose-dependent insulinotropic polypeptide), and glucagon receptors. it is the most potent weight management compound in phase 3 clinical research as of 2026. phase 2 data showed 24.2% mean weight loss at 48 weeks with no plateau. triumph-4 phase 3 data reported 26-29% mean weight loss at 48-68 weeks -- the highest ever recorded in a controlled pharmaceutical obesity trial -- with participants still actively losing weight at study end. the glucagon receptor component uniquely adds resting metabolic rate increase and hepatic fat oxidation on top of the appetite suppression driven by glp-1/gip agonism, producing additive weight loss that mono- and dual agonists cannot match. masld (metabolic dysfunction-associated steatotic liver disease) normalization occurred in approximately 93% of participants in sub-studies, with more than 80% reduction in liver fat content. lean mass is largely preserved through gip receptor co-activation. gastrointestinal tolerability is comparable to tirzepatide and better than semaglutide at equivalent weight-loss-producing doses -- partly because gip co-agonism buffers the gi side effects of glp-1 agonism. also known as glp-3 or glp-3 r in some research supply catalogs. as of may 2026, retatrutide has not received fda approval and remains a research compound. for research and educational purposes only.

Specifications

Dose Calculator